We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+24.47%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.91B
AUM Growth
+$85.7M
Cap. Flow
-$231M
Cap. Flow %
-12.11%
Top 10 Hldgs %
76.45%
Holding
46
New
3
Increased
22
Reduced
1
Closed
5

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$60.4M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$33.5M
3
EHTH icon
eHealth
EHTH
+$23.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$23.3M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$17.6M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$413M
2
AMAG
AMAG Pharmaceuticals
AMAG
+$28.2M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$1.55M
4
EOLS icon
Evolus
EOLS
+$1.04M
5
AIMT
Aimmune Therapeutics
AIMT
+$682K

Sector Composition

Rank Sector Weight
1 Healthcare 97.42%
2 Financials 2.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.24B
$226M 11.83%
2,849,348
+57,655
+2% +$4.22M
INSM icon
2
Insmed
INSM
$29B
$203M 10.66%
6,105,980
+73,024
+1% +$2.67M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$13.5B
$189M 9.91%
2,155,050
+422,500
+24% +$33.5M
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$182M 9.52%
7,867,114
– –
ABMD
5
DELISTED
Abiomed Inc
ABMD
$180M 9.46%
556,633
+52,600
+10% +$14.5M
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$5.07B
$123M 6.45%
2,301,477
+469,177
+26% +$23.3M
UTHR icon
7
United Therapeutics
UTHR
$22.1B
$119M 6.25%
785,406
– –
KPTI icon
8
Karyopharm Therapeutics
KPTI
$47.6M
$81.5M 4.27%
351,177
+12,100
+4% +$2.8M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$78.7M 4.12%
503,429
+45,900
+10% +$5.9M
RVNC
10
DELISTED
Revance Therapeutics, Inc.
RVNC
$75.8M 3.97%
2,673,313
+678,408
+34% +$17.6M
EPZM
11
DELISTED
Epizyme, Inc
EPZM
$73.2M 3.84%
6,738,913
+335,313
+5% +$4.14M
BIIB icon
12
Biogen
BIIB
$30.1B
$57.4M 3.01%
+234,300
New +$60.4M
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$298M
$55.6M 2.91%
4,230,548
+60,267
+1% +$725K
SAGE
14
DELISTED
Sage Therapeutics
SAGE
$51.1M 2.68%
590,200
– –
EHTH icon
15
eHealth
EHTH
$39.1M
$41.4M 2.17%
586,999
+306,561
+109% +$23.3M
ALGN icon
16
Align Technology
ALGN
$12.3B
$36.1M 1.89%
67,505
– –
CLVS
17
DELISTED
Clovis Oncology, Inc.
CLVS
$21.5M 1.12%
4,469,411
– –
PRTA icon
18
Prothena Corp
PRTA
$473M
$20.3M 1.07%
1,691,805
+363,071
+27% +$4.29M
GOSS icon
19
Gossamer Bio
GOSS
$88.9M
$16.8M 0.88%
1,739,050
+661,850
+61% +$6.52M
PBYI icon
20
Puma Biotechnology
PBYI
$453M
$14.1M 0.74%
1,373,897
+5,580
+0.4% +$56.5K
ANAB icon
21
AnaptysBio
ANAB
$1.71B
$8.95M 0.47%
416,292
+47,570
+13% +$1.16M
DRNA
22
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.31M 0.38%
331,813
– –
KLDO
23
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$7.16M 0.38%
786,400
– –
SNDX icon
24
Syndax Pharmaceuticals
SNDX
$1.81B
$5.88M 0.31%
264,200
+65,800
+33% +$1.36M
TVTX icon
25
Travere Therapeutics
TVTX
$5.68B
$4.3M 0.23%
157,900
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q4 2020 Portfolio in Review

As of Q4 2020, Palo Alto Investors held 46 positions worth $1.91B, up 4.7% from $1.82B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Palo Alto Investors withdrew a net $231M in Q4 2020, closing 5 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $413M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 74% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors opened a new position in Biogen worth $57.4M.

  • Palo Alto Investors's largest Q4 2020 buy was Biogen: 234,300 shares worth $57.4M.
  • Palo Alto Investors added most to BioMarin Pharmaceuticals in Q4 2020, an estimated $33.5M increase.
  • Palo Alto Investors's biggest Q4 2020 reduction was Rigel Pharmaceuticals, cutting an estimated $538K.
  • Palo Alto Investors fully exited Immunomedics Inc in Q4 2020, selling an estimated $413M.
  • Palo Alto Investors's ten largest holdings make up 76% of its $1.91B portfolio in Q4 2020.
  • Palo Alto Investors opened 3 new positions and closed 5 in Q4 2020.
  • Palo Alto Investors's portfolio value rose 4.7% quarter-over-quarter to $1.91B.

Based on Palo Alto Investors's 13F filing for Q4 2020, filed 16 Feb 2021.